pixel
Close modal

You are now leaving the
TIBSOVO® healthcare professional website.

Return to TibsovoPro.com
Ordering and distriution network

Ordering and distribution network

National Drug Code (NDC)

NDCs

10-digit code: 72694-617-60

11-digit code: 72694-0617-60
Dosage strength

250 mg/tablet
Description

250-mg tablet: Blue oval-shaped film-coated tablet debossed “IVO” on one side and “250” on the other side

The red zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.

ivo-with-2-pills

Product information

How TIBSOVO is supplied: 250-mg tablets, supplied in 60-count bottles (30-day supply) with a desiccant canister

Storage: Store at 20 to 25 ºC (68 to 77 ºF)

Distribution network for TIBSOVO

TIBSOVO is only available through our specialty distributors and network specialty pharmacies.

Building icon

Specialty distributors

TIBSOVO is available through specialty distributors for shipment directly to office- or hospital-based pharmacies.

McKesson Specialty Health

Multispecialty

Phone icon
1-855-477-9800
fax icon
1-800-800-5673
fax icon
mshcustomercare-mspl@mckesson.com
Arrow icon
mscs.mckesson.com

Oncology

Phone icon
1800-482-6700
fax icon
1-855-824-9489
fax icon
oncologycustomersupport@mckesson.com
Arrow icon
mscs.mckesson.com

Cardinal Health Specialty Pharmaceutical Distribution (US)

Physician Office

Phone icon
1-877-453-3972
Email icon
spdoncologyteam@cardinalhealth.com
Arrow icon
specialtyonline.cardinalhealth.com

Hospitals/All Other

Phone icon
1-866-677-4844
Fax icon
1-614-652-7043
Email icon
gmb-spd-csorderentry@cardinalhealth.com
Arrow icon
orderexpress.cardinalhealth.com

Cardinal Health (Puerto Rico)

Phone icon
1-787-625-4100
Fax icon
1-787-625-4397
Email icon
infopr@cardinalhealth.com
Arrow icon
cardinalhealth.pr

ASD Healthcare

Phone icon
1-800-746-6273
Fax icon
1-800-547-9413
Email icon
service@asdhealthcare.com
Arrow icon
asdhealthcare.com

Oncology Supply

Phone icon
1-800-633-7555
Fax icon
1-800-248-8205
Email icon
service@oncologysupply.com
Arrow icon
oncologysupply.com
Pharmacies icon

Network specialty pharmacies

TIBSOVO ships directly from the specialty pharmacy to your patient’s home or preferred location.

Biologics by McKesson

Phone icon
1-800-850-4306
Fax icon
1-800-823-4506
Email icon
mycareteam@biologicsinc.com
Arrow icon
biologics.mckesson.com

Onco360

Phone icon
1-877-662-6633
Phone icon
1-877-662-6355
Email icon
CustomerCare@onco360.com
Arrow icon
Onco360.com
Back
to top
Patient support services
Servier One

Patient support services

ServierONE offers patients helpful resources and tools for navigating treatment care, costs, and education throughout their journey.

ServierONE Patient Support Services for TIBSOVO (ivosidenib tablets) includes:
  • Tick iconSupport with insurance coverage and reimbursement
  • Dollar iconFinancial assistance to help patients pay for TIBSOVO
  • Prescription iconPrescription fulfillment through our network of specialty pharmacies and distributors

To receive more information

Click icon
VISIT ServierONE.com
OR
Call icon
CALL 1-800-813-5905
Back
to top
 
See FAQs for TIBSOVO ›

TIBSOVO® (ivosidenib tablets) was studied in a phase 3, randomized, double-blind, placebo-controlled, multicenter trial—one of the largest clinical trials to date of a targeted therapy in cholangiocarcinoma1-3

cca-efficacy-modal cca-efficacy-modal

CCA, cholangiocarcinoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IDH1, isocitrate dehydrogenase-1; mIDH1, mutated IDH1; NGS, next-generation sequencing; QD, once a day; RECIST, Response Evaluation Criteria in Solid Tumors.

References: 1. Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2022. 2. Data on file. Servier Pharmaceuticals LLC. 3. Zhu AX, Macarulla T, Javle MM, et al. Final results from the ClarIDHy Phase III study of ivosidenib versus placebo in patients with previously treated cholangiocarcinoma and an isocitrate dehydrogenase 1 (IDH1) mutation. EMJ Oncol. 2021;9(suppl 2):2-5. doi:10.1200/JCO.2021.39.3_suppl.266

TIBSOVO® was studied in a patient population reflective of that seen in a clinical practice1,2

Selected baseline demographics and disease characteristics (N=185)1

  TIBSOVO
(n=124)		 Placebo
(n=61)
Demographics
Median age, years (min, max) 61 (33,80) 63 (40,83)
Sex
Male 36% 40%
Female 65% 61%
Race
White 57% 57%
Asian 12% 13%
Black 0.8% 1.6%
Native Hawaiian/Other Pacific Islander 0.8% 0%
American Indian or Alaska Native 0.8% 0
Disease characteristics
Prior lines of therapy
1 prior line of therapy 53% 54%
2 prior lines of therapy 47% 46%
ECOG PS
0 40% 31%
1 60% 67%
IDH1 mutation
R132C 68% 74%
R132L 17% 12%
R132G 14% 10%
R132H 0% 3.3%
R132S 1.6% 1.6%
Cholangiocarcinoma type at initial diagnosis
Intrahepatic 90% 95%
Metastatic disease 93% 92%

ECOG PS: Eastern Cooperative Oncology Group Performance Status.

References: 1.  Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2023. 2. Data on file. Servier Pharmaceuticals LLC.

 

Indication

TIBSOVO is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

QTc Interval Prolongation: Patients treated with TIBSOVO can develop QT (QTc) prolongation and ventricular arrhythmias. Concomitant use of TIBSOVO with drugs known to prolong the QTc interval (eg, anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or in those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary.

Interrupt TIBSOVO if QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVO if QTc increases to greater than 500 msec. Permanently discontinue TIBSOVO in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.

Guillain-Barré Syndrome: Guillain-Barré syndrome can develop in patients treated with TIBSOVO. Monitor patients taking TIBSOVO for onset of new signs or symptoms of motor and/or sensory neuropathy such as unilateral or bilateral weakness, sensory alterations, paresthesias, or difficulty breathing. Permanently discontinue TIBSOVO in patients who are diagnosed with Guillain-Barré syndrome.

ADVERSE REACTIONS

  • In patients with cholangiocarcinoma, the most common adverse reactions (≥15%) were fatigue, nausea, abdominal pain, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, and rash. The most common laboratory abnormalities (≥10%) were hemoglobin decreased, aspartate aminotransferase increased, and bilirubin increased.

DRUG INTERACTIONS

Strong or Moderate CYP3A4 Inhibitors: Reduce TIBSOVO dose with strong CYP3A4 inhibitors. Monitor patients for increased risk of QTc interval prolongation.

Strong CYP3A4 Inducers: Avoid concomitant use with TIBSOVO.

Sensitive CYP3A4 Substrates: Avoid concomitant use with TIBSOVO.

QTc Prolonging Drugs: Avoid concomitant use with TIBSOVO. If co-administration is unavoidable, monitor patients for increased risk of QTc interval prolongation.

LACTATION

Advise women not to breastfeed.

Please see Full Prescribing Information.

pixel pixel
 

Indication & Important Safety Information

INDICATION

TIBSOVO is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

QTc Interval Prolongation: Patients treated with TIBSOVO can develop QT (QTc) prolongation and ventricular arrhythmias. Concomitant use of TIBSOVO with drugs known to prolong the QTc interval (eg, anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or in those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Interrupt TIBSOVO if QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVO if QTc increases to greater than 500 msec. Permanently discontinue TIBSOVO in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.